Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Nov;70(5):786–794. doi: 10.1038/bjc.1994.400

Targeting enzymes for cancer therapy: old enzymes in new roles.

M P Deonarain 1, A A Epenetos 1
PMCID: PMC2033521  PMID: 7947082

Abstract

Enzymes which traditionally have played no role in cell-directed cytotoxicity are finding their way into schemes for prodrug activation and immunotoxins owing to such useful enzymatic activity. Alkaline phosphatase, carboxypeptidases, beta-glucosidases and beta-lactamases among many others are being utilised to regenerate potent anti-cancer drugs or toxic small molecules from precursors in a bid to enhance their activity in tumours. These prodrug activation systems require the pretargeting of the enzyme to the surface of a tumour cell, usually by an antibody or its immunoreactive fragment. A recent novel approach proposes the intracellular delivery of appropriate enzymes, such as phosphodiesterases, to particular cellular compartments. There, enzyme activity can cause substantive damage resulting in cell death. Cell targeting of mammalian phosphodiesterase promises to improve upon conventional immunotoxins because of their increased cytotoxicity when targeted to the appropriate compartment and their expected lack of, or lower, immunogenicity in clinical use.

Full text

PDF
786

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams G. P., McCartney J. E., Tai M. S., Oppermann H., Huston J. S., Stafford W. F., 3rd, Bookman M. A., Fand I., Houston L. L., Weiner L. M. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res. 1993 Sep 1;53(17):4026–4034. [PubMed] [Google Scholar]
  2. Anlezark G. M., Melton R. G., Sherwood R. F., Coles B., Friedlos F., Knox R. J. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--I. Purification and properties of a nitroreductase enzyme from Escherichia coli--a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem Pharmacol. 1992 Dec 15;44(12):2289–2295. doi: 10.1016/0006-2952(92)90671-5. [DOI] [PubMed] [Google Scholar]
  3. Bagshawe K. D. Antibody directed enzymes revive anti-cancer prodrugs concept. Br J Cancer. 1987 Nov;56(5):531–532. doi: 10.1038/bjc.1987.237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bagshawe K. D., Springer C. J., Searle F., Antoniw P., Sharma S. K., Melton R. G., Sherwood R. F. A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer. 1988 Dec;58(6):700–703. doi: 10.1038/bjc.1988.293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bignami G. S., Senter P. D., Grothaus P. G., Fischer K. J., Humphreys T., Wallace P. M. N-(4'-hydroxyphenylacetyl)palytoxin: a palytoxin prodrug that can be activated by a monoclonal antibody-penicillin G amidase conjugate. Cancer Res. 1992 Oct 15;52(20):5759–5764. [PubMed] [Google Scholar]
  6. Bird R. E., Hardman K. D., Jacobson J. W., Johnson S., Kaufman B. M., Lee S. M., Lee T., Pope S. H., Riordan G. S., Whitlow M. Single-chain antigen-binding proteins. Science. 1988 Oct 21;242(4877):423–426. doi: 10.1126/science.3140379. [DOI] [PubMed] [Google Scholar]
  7. Bosslet K., Czech J., Hoffmann D. Tumor-selective prodrug activation by fusion protein-mediated catalysis. Cancer Res. 1994 Apr 15;54(8):2151–2159. [PubMed] [Google Scholar]
  8. Byers V. S., Rodvien R., Grant K., Durrant L. G., Hudson K. H., Baldwin R. W., Scannon P. J. Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer. Cancer Res. 1989 Nov 1;49(21):6153–6160. [PubMed] [Google Scholar]
  9. Chester K. A., Begent R. H., Robson L., Keep P., Pedley R. B., Boden J. A., Boxer G., Green A., Winter G., Cochet O. Phage libraries for generation of clinically useful antibodies. Lancet. 1994 Feb 19;343(8895):455–456. doi: 10.1016/s0140-6736(94)92695-6. [DOI] [PubMed] [Google Scholar]
  10. Connors T. A., Whisson M. E. Cure of mice bearing advanced plasma cell tumours with aniline mustard: the relationship between glucuronidase activity and tumour sensitivity. Nature. 1966 May 21;210(5038):866–867. doi: 10.1038/210866b0. [DOI] [PubMed] [Google Scholar]
  11. Del Vecchio S., Reynolds J. C., Carrasquillo J. A., Blasberg R. G., Neumann R. D., Lotze M. T., Bryant G. J., Farkas R. J., Larson S. M. Local distribution and concentration of intravenously injected 131I-9.2.27 monoclonal antibody in human malignant melanoma. Cancer Res. 1989 May 15;49(10):2783–2789. [PubMed] [Google Scholar]
  12. Dinota A., Tazzari P. L., Abbondanza A., Battelli M. G., Gobbi M., Stirpe F. Bone marrow purging by a xanthine oxidase-antibody conjugate. Bone Marrow Transplant. 1990 Jul;6(1):31–36. [PubMed] [Google Scholar]
  13. Edwards P. A. Heterogeneous expression of cell-surface antigens in normal epithelia and their tumours, revealed by monoclonal antibodies. Br J Cancer. 1985 Feb;51(2):149–160. doi: 10.1038/bjc.1985.24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Epenetos A. A., Snook D., Durbin H., Johnson P. M., Taylor-Papadimitriou J. Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms. Cancer Res. 1986 Jun;46(6):3183–3191. [PubMed] [Google Scholar]
  15. Epenetos A. A., Snook D., Hooker G., Begent R., Durbin H., Oliver R. T., Bodmer W. F., Lavender J. P. Indium-111 labelled monoclonal antibody to placental alkaline phosphatase in in the detection of neoplasms of testis, ovary, and cervix. Lancet. 1985 Aug 17;2(8451):350–353. doi: 10.1016/s0140-6736(85)92495-x. [DOI] [PubMed] [Google Scholar]
  16. Glennie M. J., Brennand D. M., Bryden F., McBride H. M., Stirpe F., Worth A. T., Stevenson G. T. Bispecific F(ab' gamma)2 antibody for the delivery of saporin in the treatment of lymphoma. J Immunol. 1988 Nov 15;141(10):3662–3670. [PubMed] [Google Scholar]
  17. Glukhov B. N., Jerusalimsky A. P., Canter V. M., Salganik R. I. Ribonuclease treatment of tick-borne encephalitis. Arch Neurol. 1976 Sep;33(9):598–603. doi: 10.1001/archneur.1976.00500090004002. [DOI] [PubMed] [Google Scholar]
  18. Gould B. J., Borowitz M. J., Groves E. S., Carter P. W., Anthony D., Weiner L. M., Frankel A. E. Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies. J Natl Cancer Inst. 1989 May 10;81(10):775–781. doi: 10.1093/jnci/81.10.775. [DOI] [PubMed] [Google Scholar]
  19. Gutierrez A. A., Lemoine N. R., Sikora K. Gene therapy for cancer. Lancet. 1992 Mar 21;339(8795):715–721. doi: 10.1016/0140-6736(92)90606-4. [DOI] [PubMed] [Google Scholar]
  20. Haenseler E., Esswein A., Vitols K. S., Montejano Y., Mueller B. M., Reisfeld R. A., Huennekens F. M. Activation of methotrexate-alpha-alanine by carboxypeptidase A-monoclonal antibody conjugate. Biochemistry. 1992 Jan 28;31(3):891–897. doi: 10.1021/bi00118a035. [DOI] [PubMed] [Google Scholar]
  21. Haisma H. J., Boven E., van Muijen M., De Vries R., Pinedo H. M. Analysis of a conjugate between anti-carcinoembryonic antigen monoclonal antibody and alkaline phosphatase for specific activation of the prodrug etoposide phosphate. Cancer Immunol Immunother. 1992;34(5):343–348. doi: 10.1007/BF01741556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Haisma H. J., Boven E., van Muijen M., de Jong J., van der Vijgh W. J., Pinedo H. M. A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer. Br J Cancer. 1992 Sep;66(3):474–478. doi: 10.1038/bjc.1992.298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Harris J. D., Gutierrez A. A., Hurst H. C., Sikora K., Lemoine N. R. Gene therapy for cancer using tumour-specific prodrug activation. Gene Ther. 1994 May;1(3):170–175. [PubMed] [Google Scholar]
  24. Huston J. S., Levinson D., Mudgett-Hunter M., Tai M. S., Novotný J., Margolies M. N., Ridge R. J., Bruccoleri R. E., Haber E., Crea R. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci U S A. 1988 Aug;85(16):5879–5883. doi: 10.1073/pnas.85.16.5879. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Ito H., Morizet J., Coulombel L., Stanislawski M. T cell depletion of human bone marrow using an oxidase-peroxidase enzyme immunotoxin. Bone Marrow Transplant. 1990 Dec;6(6):395–398. [PubMed] [Google Scholar]
  26. Kerr D. E., Senter P. D., Burnett W. V., Hirschberg D. L., Hellström I., Hellström K. E. Antibody-penicillin-V-amidase conjugates kill antigen-positive tumor cells when combined with doxorubicin phenoxyacetamide. Cancer Immunol Immunother. 1990;31(4):202–206. doi: 10.1007/BF01789169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Köhler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975 Aug 7;256(5517):495–497. doi: 10.1038/256495a0. [DOI] [PubMed] [Google Scholar]
  28. Laccetti P., Portella G., Mastronicola M. R., Russo A., Piccoli R., D'Alessio G., Vecchio G. In vivo and in vitro growth-inhibitory effect of bovine seminal ribonuclease on a system of rat thyroid epithelial transformed cells and tumors. Cancer Res. 1992 Sep 1;52(17):4582–4586. [PubMed] [Google Scholar]
  29. Ledermann J. A., Begent R. H., Bagshawe K. D., Riggs S. J., Searle F., Glaser M. G., Green A. J., Dale R. G. Repeated antitumour antibody therapy in man with suppression of the host response by cyclosporin A. Br J Cancer. 1988 Nov;58(5):654–657. doi: 10.1038/bjc.1988.279. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Marasco W. A., Haseltine W. A., Chen S. Y. Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7889–7893. doi: 10.1073/pnas.90.16.7889. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Martin S. J., Green D. R., Cotter T. G. Dicing with death: dissecting the components of the apoptosis machinery. Trends Biochem Sci. 1994 Jan;19(1):26–30. doi: 10.1016/0968-0004(94)90170-8. [DOI] [PubMed] [Google Scholar]
  32. Meyer D. L., Jungheim L. N., Mikolajczyk S. D., Shepherd T. A., Starling J. J., Ahlem C. N. Preparation and characterization of a beta-lactamase-Fab' conjugate for the site-specific activation of oncolytic agents. Bioconjug Chem. 1992 Jan-Feb;3(1):42–48. doi: 10.1021/bc00013a007. [DOI] [PubMed] [Google Scholar]
  33. Miyashita H., Karaki Y., Kikuchi M., Fujii I. Prodrug activation via catalytic antibodies. Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5337–5340. doi: 10.1073/pnas.90.11.5337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Moolten F. L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 1986 Oct;46(10):5276–5281. [PubMed] [Google Scholar]
  35. Mullen C. A., Kilstrup M., Blaese R. M. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):33–37. doi: 10.1073/pnas.89.1.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Muzykantov V. R., Sakharov D. V., Sinitsyn V. V., Domogatsky S. P., Goncharov N. V., Danilov S. M. Specific killing of human endothelial cells by antibody-conjugated glucose oxidase. Anal Biochem. 1988 Mar;169(2):383–389. doi: 10.1016/0003-2697(88)90300-4. [DOI] [PubMed] [Google Scholar]
  37. Muzykantov V. R., Trubetskaya O. V., Puchnina E. A., Sakharov D. V., Domogatsky S. P. Cytotoxicity of glucose oxidase conjugated with antibodies to target cells: killing efficiency depends on the conjugate internalization. Biochim Biophys Acta. 1990 Jun 12;1053(1):27–31. doi: 10.1016/0167-4889(90)90021-5. [DOI] [PubMed] [Google Scholar]
  38. Neuberger M. S., Williams G. T., Fox R. O. Recombinant antibodies possessing novel effector functions. Nature. 1984 Dec 13;312(5995):604–608. doi: 10.1038/312604a0. [DOI] [PubMed] [Google Scholar]
  39. Newton D. L., Ilercil O., Laske D. W., Oldfield E., Rybak S. M., Youle R. J. Cytotoxic ribonuclease chimeras. Targeted tumoricidal activity in vitro and in vivo. J Biol Chem. 1992 Sep 25;267(27):19572–19578. [PubMed] [Google Scholar]
  40. Philpott G. W., Shearer W. T., Bower R. J., Parker C. W. Selective cytotoxicity of hapten-substituted cells with an antibody-enzyme conjugate. J Immunol. 1973 Sep;111(3):921–929. [PubMed] [Google Scholar]
  41. Riechmann L., Clark M., Waldmann H., Winter G. Reshaping human antibodies for therapy. Nature. 1988 Mar 24;332(6162):323–327. doi: 10.1038/332323a0. [DOI] [PubMed] [Google Scholar]
  42. Roffler S. R., Wang S. M., Chern J. W., Yeh M. Y., Tung E. Anti-neoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate. Biochem Pharmacol. 1991 Oct 24;42(10):2062–2065. doi: 10.1016/0006-2952(91)90612-9. [DOI] [PubMed] [Google Scholar]
  43. Rybak S. M., Hoogenboom H. R., Meade H. M., Raus J. C., Schwartz D., Youle R. J. Humanization of immunotoxins. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3165–3169. doi: 10.1073/pnas.89.8.3165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Rybak S. M., Saxena S. K., Ackerman E. J., Youle R. J. Cytotoxic potential of ribonuclease and ribonuclease hybrid proteins. J Biol Chem. 1991 Nov 5;266(31):21202–21207. [PubMed] [Google Scholar]
  45. Sahin U., Hartmann F., Senter P., Pohl C., Engert A., Diehl V., Pfreundschuh M. Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody. Cancer Res. 1990 Nov 1;50(21):6944–6948. [PubMed] [Google Scholar]
  46. Sakharov D. V., Muzykantov V. R., Domogatsky S. P., Danilov S. M. Protection of cultured endothelial cells from hydrogen peroxide-induced injury by antibody-conjugated catalase. Biochim Biophys Acta. 1987 Sep 14;930(2):140–144. doi: 10.1016/0167-4889(87)90025-5. [DOI] [PubMed] [Google Scholar]
  47. Sehon A. H. Modulation of antibody responses by conjugates of antigens with monomethoxypolyethylene glycol. Adv Exp Med Biol. 1989;251:341–351. doi: 10.1007/978-1-4757-2046-4_30. [DOI] [PubMed] [Google Scholar]
  48. Senter P. D., Saulnier M. G., Schreiber G. J., Hirschberg D. L., Brown J. P., Hellström I., Hellström K. E. Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci U S A. 1988 Jul;85(13):4842–4846. doi: 10.1073/pnas.85.13.4842. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Senter P. D., Su P. C., Katsuragi T., Sakai T., Cosand W. L., Hellström I., Hellström K. E. Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugates. Bioconjug Chem. 1991 Nov-Dec;2(6):447–451. doi: 10.1021/bc00012a012. [DOI] [PubMed] [Google Scholar]
  50. Sharma S. K., Bagshawe K. D., Springer C. J., Burke P. J., Rogers G. T., Boden J. A., Antoniw P., Melton R. G., Sherwood R. F. Antibody directed enzyme prodrug therapy (ADEPT): a three phase system. Dis Markers. 1991 May-Aug;9(3-4):225–231. [PubMed] [Google Scholar]
  51. Springer C. J., Bagshawe K. D., Sharma S. K., Searle F., Boden J. A., Antoniw P., Burke P. J., Rogers G. T., Sherwood R. F., Melton R. G. Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. Eur J Cancer. 1991;27(11):1361–1366. doi: 10.1016/0277-5379(91)90010-b. [DOI] [PubMed] [Google Scholar]
  52. Stanislawski M., Rousseau V., Goavec M., Ito H. Immunotoxins containing glucose oxidase and lactoperoxidase with tumoricidal properties: in vitro killing effectiveness in a mouse plasmacytoma cell model. Cancer Res. 1989 Oct 15;49(20):5497–5504. [PubMed] [Google Scholar]
  53. Sunters A., Baer J., Bagshawe K. D. Cytotoxicity and activation of CB1954 in a human tumour cell line. Biochem Pharmacol. 1991 May 1;41(9):1293–1298. doi: 10.1016/0006-2952(91)90100-j. [DOI] [PubMed] [Google Scholar]
  54. Svensson H. P., Kadow J. F., Vrudhula V. M., Wallace P. M., Senter P. D. Monoclonal antibody-beta-lactamase conjugates for the activation of a cephalosporin mustard prodrug. Bioconjug Chem. 1992 Mar-Apr;3(2):176–181. doi: 10.1021/bc00014a013. [DOI] [PubMed] [Google Scholar]
  55. Tannock I. F., Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 1989 Aug 15;49(16):4373–4384. [PubMed] [Google Scholar]
  56. Valeriote F., van Putten L. Proliferation-dependent cytotoxicity of anticancer agents: a review. Cancer Res. 1975 Oct;35(10):2619–2630. [PubMed] [Google Scholar]
  57. Vingerhoeds M. H., Haisma H. J., van Muijen M., van de Rijt R. B., Crommelin D. J., Storm G. A new application for liposomes in cancer therapy. Immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific activation of prodrugs. FEBS Lett. 1993 Dec 28;336(3):485–490. doi: 10.1016/0014-5793(93)80861-n. [DOI] [PubMed] [Google Scholar]
  58. Vitetta E. S., Thorpe P. E., Uhr J. W. Immunotoxins: magic bullets or misguided missiles? Trends Pharmacol Sci. 1993 May;14(5):148–154. doi: 10.1016/0165-6147(93)90199-t. [DOI] [PubMed] [Google Scholar]
  59. Waldmann T. A. Monoclonal antibodies in diagnosis and therapy. Science. 1991 Jun 21;252(5013):1657–1662. doi: 10.1126/science.2047874. [DOI] [PubMed] [Google Scholar]
  60. Weiner L. M., O'Dwyer J., Kitson J., Comis R. L., Frankel A. E., Bauer R. J., Konrad M. S., Groves E. S. Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate. Cancer Res. 1989 Jul 15;49(14):4062–4067. [PubMed] [Google Scholar]
  61. Worrall A. F., Connolly B. A. The chemical synthesis of a gene coding for bovine pancreatic DNase I and its cloning and expression in Escherichia coli. J Biol Chem. 1990 Dec 15;265(35):21889–21895. [PubMed] [Google Scholar]
  62. Wu Y., Mikulski S. M., Ardelt W., Rybak S. M., Youle R. J. A cytotoxic ribonuclease. Study of the mechanism of onconase cytotoxicity. J Biol Chem. 1993 May 15;268(14):10686–10693. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES